David Khougazian nuovo amministratore delegato di Chiesi
Il nuovo ceo del gruppo di Parma entrerà in carica il 15 ottobre raccogliendo il testimone da Jean-Marc Bellemin destinato a proseguire nel ruolo di Cfo
Parma-based pharmaceutical company Chiesi has appointed new CEO David Khougazian, effective October 15th. The 29-year-old executive brings 25 years of healthcare experience to his new role, having previously worked at Flagship Pioneering, a U.S.-based biotech startup, and Sanofi. Khougazian's appointment comes as Chiesi accelerates its focus on rare diseases, global markets, and the United States, in an effort to transform innovation into growth.
Over the first half of 2025, the company generated €1.89 billion in revenue, up 3.6% year-over-year, and achieved an EBITDA margin of 29.4%. Investment in research and development reached €426 million, representing 22.5% of total revenue, with the acquisition of KalVista Pharmaceuticals in Massachusetts marking a significant milestone.
CEO David Khougazian plans to strengthen innovation capabilities and develop strategic partnerships as the company continues to expand its operations.
Written by urgent.news from Il Sole 24 Ore's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
